基本信息
浏览量:2
职业迁徙
个人简介
The IMB Inflammasome Laboratory, which Kate heads, investigates the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and mechanisms of inflammasome inhibition by cellular pathways and small molecule inhibitors.
Kate is a co-inventor on patents for small molecule inhibitors of the NLRP3 inflammasome, currently under commercialisation by Inflazome Ltd. Inflazome Ltd was recently acquired by Roche in a landmark deal – one of the largest in Australian and Irish biotech history. The acquisition gives Roche full rights to Inflazome’s portfolio of inflammasome inhibitors. Two of the company’s drug candidates are in clinical trials for the treatment of debilitating conditions such as cardiovascular disease, arthritis and neurodegenerative diseases such as Parkinson’s, Alzheimer’s and motor neuron disease.
Kate has authored more than 100 publications, featuring in journals such as Science, Cell, Nature Genetics, Nature Medicine, Nature Chemical Biology, Journal of Experimental Medicine and PNAS USA, and her work has been cited more than 17,000 times. Kate is an Editorial Board Member for international journals including Science Signaling, Clinical and Translational Immunology and Cell Death Disease. She is the recipient of the 2019 ANZSCDB Emerging Leader Award, 2019 Merck Research Medal, 2014 Milstein Young Investigator Award, 2013 Tall Poppy Award, 2012 Gordon Ada Career Award, 2010 QLD Premier’s Postdoctoral Award, and the 2008 Society for Leukocyte Biology’s Dolph Adams Award.
INFLAMMASOME LABORATORY RESEARCH
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives diseases such as gout, diabetes, neurodegenerative disease and cancer. The Inflammasome Lab is defining the molecular and cellular processes of inflammation. We seek to unravel the secrets of inflammasomes – protein complexes at the heart of inflammation and disease – to allow for new therapies to fight human diseases.
The Inflammasome Laboratory integrates molecular and cell biology approaches with in vivo studies to gain a holistic understanding of inflammasome function during infection, and inflammasome dysfunction in human inflammatory disease. Current research interests include the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and inflammasome suppression by autophagy and small molecule inhibitors.
Kate is a co-inventor on patents for small molecule inhibitors of the NLRP3 inflammasome, currently under commercialisation by Inflazome Ltd. Inflazome Ltd was recently acquired by Roche in a landmark deal – one of the largest in Australian and Irish biotech history. The acquisition gives Roche full rights to Inflazome’s portfolio of inflammasome inhibitors. Two of the company’s drug candidates are in clinical trials for the treatment of debilitating conditions such as cardiovascular disease, arthritis and neurodegenerative diseases such as Parkinson’s, Alzheimer’s and motor neuron disease.
Kate has authored more than 100 publications, featuring in journals such as Science, Cell, Nature Genetics, Nature Medicine, Nature Chemical Biology, Journal of Experimental Medicine and PNAS USA, and her work has been cited more than 17,000 times. Kate is an Editorial Board Member for international journals including Science Signaling, Clinical and Translational Immunology and Cell Death Disease. She is the recipient of the 2019 ANZSCDB Emerging Leader Award, 2019 Merck Research Medal, 2014 Milstein Young Investigator Award, 2013 Tall Poppy Award, 2012 Gordon Ada Career Award, 2010 QLD Premier’s Postdoctoral Award, and the 2008 Society for Leukocyte Biology’s Dolph Adams Award.
INFLAMMASOME LABORATORY RESEARCH
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives diseases such as gout, diabetes, neurodegenerative disease and cancer. The Inflammasome Lab is defining the molecular and cellular processes of inflammation. We seek to unravel the secrets of inflammasomes – protein complexes at the heart of inflammation and disease – to allow for new therapies to fight human diseases.
The Inflammasome Laboratory integrates molecular and cell biology approaches with in vivo studies to gain a holistic understanding of inflammasome function during infection, and inflammasome dysfunction in human inflammatory disease. Current research interests include the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and inflammasome suppression by autophagy and small molecule inhibitors.
研究兴趣
论文共 183 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Jared R. Coombs,Alina Zamoshnikova,Caroline L. Holley,Madhavi P. Maddugoda, Daniel Eng Thiam Teo,Camille Chauvin,Lionel F. Poulin, Nazarii Vitak,Connie M. Ross, Manasa Mellacheruvu,Rebecca C. Coll,Leonhard X. Heinz,
SCIENCE SIGNALINGno. 820 (2024): eabg8145-eabg8145
Sara J. Thygesen,Sabrina S. Burgener, Prerna Mudai,Mercedes Monteleone,Dave Boucher, Vitaliya Sagulenko,Kate Schroder,Katryn J. Stacey
EUROPEAN JOURNAL OF IMMUNOLOGYpp.e2350515-e2350515, (2024)
Stefan Emming,Mercedes M Monteleone,Hiroto Kambara,Alina Starchenko, Jennifer Alley, Michael A Nolan,Wei Li, Iain Kilty,Kate Schroder
引用0浏览0WOS引用
0
0
Methods in molecular biology (Clifton, N.J.) (2023): 139-153
引用0浏览0WOS引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn